- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (25)
28 result(s) found for: RAGE.
Displaying page 1 of 2.
EudraCT Number: 2022-003466-20 | Sponsor Protocol Number: ARORAGE-1001 | Start Date*: 2023-06-01 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 1/2a Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000441-58 | Sponsor Protocol Number: 08005DM-A | Start Date*: 2009-01-22 |
Sponsor Name:Belfast City Hospital | ||
Full Title: Investigation of the protective effects of keratinocyte growth factor (KGF) in a human lipopolysaccharide induced model of acute lung injury | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003197-17 | Sponsor Protocol Number: 3239E | Start Date*: 2006-09-13 |
Sponsor Name:Cardiff and Vale NHS Trust | ||
Full Title: The Metabolic,Vascular and Inflammatory effects of Conjugated Linoleic acid in patients with the Metabolic Syndrome. | ||
Medical condition: METABOLIC SYNDROME | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005173-23 | Sponsor Protocol Number: V49_23 | Start Date*: 2012-03-08 | |||||||||||||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics GmbH | |||||||||||||||||||||||
Full Title: A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Differ... | |||||||||||||||||||||||
Medical condition: Safety and Immunogenicity of Rabies Vaccine and Japanese Encephalitis Vaccine administered concomitantly and/or separately according to 1 of 2 different pre-exposure prophylaxis schedules to health... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014532-37 | Sponsor Protocol Number: JU-AMG-403-1-1 | Start Date*: 2011-01-13 |
Sponsor Name:Universitätsklinikum Schleswig-Holstein | ||
Full Title: Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie). | ||
Medical condition: alkohol dependence | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002367-29 | Sponsor Protocol Number: ITM202203 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:Instituut van Tropische Geneeskunde Antwerpen | |||||||||||||
Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies... | |||||||||||||
Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000382-31 | Sponsor Protocol Number: 205214 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals S.A. | |||||||||||||
Full Title: A Phase III, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Pr... | |||||||||||||
Medical condition: Rabies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004008-36 | Sponsor Protocol Number: VRV09 | Start Date*: 2020-09-07 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine– Serum Free (VRVg) Assessed with the Institut Pasteur du Cambodge (IPC: 2-2-2-0-0) and the Thai Red Cross (TRC: 2-2-2-0-2) Intradermal Re... | |||||||||||||
Medical condition: Rabies (Healthy Volunteers) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000973-22 | Sponsor Protocol Number: VRV12 | Start Date*: 2020-11-15 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Sing... | |||||||||||||
Medical condition: Rabies | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002096-34 | Sponsor Protocol Number: AER-2012 | Start Date*: 2012-10-29 | |||||||||||
Sponsor Name:Crucell Holland B.V. | |||||||||||||
Full Title: Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur® | |||||||||||||
Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000215-79 | Sponsor Protocol Number: RBHP 2010 Soubrier | Start Date*: 2011-06-07 |
Sponsor Name:CHU de Clermont Ferrand | ||
Full Title: Tociluzimab effect on Endothelial function in patients with Rheumatoid Arthritis | ||
Medical condition: Polyarthrite rhumatoïde | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001719-65 | Sponsor Protocol Number: CALC-SSc | Start Date*: 2018-12-10 |
Sponsor Name:University Medial Center Groningen | ||
Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study | ||
Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000089-31 | Sponsor Protocol Number: PREPARE | Start Date*: 2017-08-09 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Single dose rabies PRE-exposure Priming induces a rapid and effective anamnestic Antibody REsponse | |||||||||||||
Medical condition: healthy volunteer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004406-18 | Sponsor Protocol Number: INRCA-2017-01 | Start Date*: 2019-02-14 | |||||||||||
Sponsor Name:IRCC INRCA | |||||||||||||
Full Title: Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on pro-inflammatory and oxidative stress markers (GOOD-WP1) | |||||||||||||
Medical condition: TYPE 2 DIABETES | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017943-32 | Sponsor Protocol Number: 871 | Start Date*: 2010-05-31 | |||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||
Full Title: Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer | |||||||||||||
Medical condition: Histologically confirmed squamous cell carcinoma of the head and neck which qualifies for definitive treatment with chemoradiation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005564-21 | Sponsor Protocol Number: SIRAVA | Start Date*: 2021-12-28 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis. | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001650-26 | Sponsor Protocol Number: AnticholiumperSeIII | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D | |||||||||||||
Full Title: A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000014-38 | Sponsor Protocol Number: THX-G18-001 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:Therapix Biosciences Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”) | |||||||||||||
Medical condition: Tourette Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001223-14 | Sponsor Protocol Number: VAJ00001 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Sanofi Pasteur SA | |||||||||||||
Full Title: Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscu... | |||||||||||||
Medical condition: Rabies disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
